CSR at Galapagos – Summary
CSR at Galapagos – Summary
CSR report
Material Aspect 1: Improving people’s lives
SDG
Areas of engagement
- We are pioneering for patients and our mission is to discover and develop innovative medicines that address high unmet medical needs
- Our science and innovation is based on our flexible target discovery platform
- We commit to an ambitious R&D goal of maintaining an active portfolio of 30 projects
- We are building a deep early-stage R&D pipeline
- Pending potential approval, we expect to launch our first drug, filgotinib in RA, in 2020, with additional indications to follow in the coming years
- We aim to bring our innovation to patients suffering from severe diseases, includig in IPF
- We accelerate innovation through win-win partnerships
Material Aspect 2: Our employees are the strength behind Galapagos
SDG
Areas of engagement
- We strive for gender equality
- We aim to continue to develop an inclusive and diverse workforce
- We have implemented a program that is designed to reward, recognize and retain employees
- Our involvement in local communities and charities
Material Aspect 3: Conducting business ethically and responsibly
SDG
Areas of engagement
- Animal welfare in drug development
- Our clinical trials ethics
- Access to our medicines
- Our code of business conduct and ethics
Material Aspect 4: We care about the environment, health and safety
SDG
Areas of engagement
- We strive for a minimal environmental impact
- We are compliant with our sector rules and regulations
- We go digital as much as possible
- We established a company-wide EHS framework